Addyi Titration in Hepatic Impairment: What Women Need to Know

The short answer: there is no hepatic titration schedule for Addyi

Flibanserin cannot be titrated down to a "liver-safe" dose. The FDA-approved prescribing information states plainly that flibanserin is contraindicated in patients with hepatic impairment of any severity, mild, moderate, or severe. This is not a relative precaution or a reason to reduce the dose by half. It is a hard stop.

The reason comes down to pharmacokinetics. Flibanserin is metabolized almost entirely in the liver via CYP3A4 and CYP2C19. When hepatic function is reduced, even modestly, clearance slows and plasma concentrations climb. In pharmacokinetic studies summarized in the label, mild hepatic impairment alone raised flibanserin area-under-the-curve (AUC) by approximately fourfold compared to women with normal liver function. That is not a gap you can close with a lower starting dose.

This article explains the physiology behind that contraindication, what it means across different life stages, and what clinically appropriate alternatives exist for women with HSDD who also have liver disease.

Why the liver matters so much for flibanserin

Flibanserin's metabolic pathway

Flibanserin is a serotonin receptor agonist and antagonist. After a standard 100 mg oral dose, it reaches peak plasma concentration in roughly 45 minutes on an empty stomach, with a half-life of approximately 11 hours. Nearly all of that drug is broken down hepatically. CYP3A4 handles the dominant route; CYP2C19 and CYP1A2 contribute secondary pathways.

When hepatic cells are damaged or reduced in functional mass, as happens in nonalcoholic fatty liver disease (NAFLD), alcohol-related liver disease, viral hepatitis, cirrhosis, or cholestatic conditions, CYP enzyme activity falls. The drug lingers longer, accumulates with repeat nightly dosing, and the central nervous system, already the intended target, receives a much larger and more sustained drug signal than the clinical trial program ever tested.

What the pharmacokinetic data actually show

The label's dedicated hepatic impairment subsection reports data from subjects classified by Child-Pugh scoring. In individuals with mild hepatic impairment (Child-Pugh A), AUC was approximately 4.5-fold higher than in matched controls with normal hepatic function. The maximum plasma concentration (Cmax) rose by a similar magnitude. No formal studies were conducted in moderate (Child-Pugh B) or severe (Child-Pugh C) impairment because the mild-impairment findings alone were enough to trigger the contraindication.

This is a detail worth sitting with. "Mild" by Child-Pugh criteria is not the same as a slightly elevated ALT. A woman can have Child-Pugh A cirrhosis with relatively preserved synthetic function and still look reasonably well on routine labs. The contraindication applies to her just as it does to someone with decompensated liver disease.

The hypotension and CNS depression risk

Elevated flibanserin concentrations do not simply cause a stronger desired effect. The drug's dose-dependent adverse effects include severe hypotension and syncope, particularly when combined with alcohol or CYP3A4 inhibitors. Both risks escalate proportionally with plasma levels. A fourfold rise in AUC in a woman with mild liver disease means a woman who might have tolerated 100 mg bedtime dosing with minimal side effects could experience profound blood pressure drops, loss of consciousness, or significant CNS sedation.

The FDA required a Risk Evaluation and Mitigation Strategy (REMS) for Addyi specifically because of the hypotension and syncope risk linked to alcohol co-ingestion. Hepatic impairment adds a parallel mechanism for the same dangerous outcome.

Who this applies to across women's life stages

Reproductive-age women (roughly 18 to 45)

HSDD is the most common female sexual dysfunction, affecting an estimated 8 to 10 percent of women in this age group when defined by distress-criteria. Flibanserin is specifically approved for premenopausal women, so this is the population for whom clinicians will most often consider it.

NAFLD is increasingly common in reproductive-age women, particularly those with PCOS. Polycystic ovary syndrome is present in 6 to 12 percent of women of reproductive age, and the metabolic profile of PCOS, insulin resistance, dyslipidemia, and visceral adiposity, significantly raises NAFLD risk. A 2020 meta-analysis estimated NAFLD prevalence at nearly 40 percent among women with PCOS. This is a clinically important intersection: two common conditions, PCOS-related HSDD and PCOS-related NAFLD, can combine to make flibanserin a non-starter.

If you are a premenopausal woman with PCOS who is experiencing low sexual desire and also has elevated liver enzymes or confirmed steatosis, your clinician needs to evaluate hepatic function formally, not just check an ALT, before flibanserin is even discussed.

Perimenopause

Flibanserin is FDA-approved only for premenopausal women. Its trials did not enroll perimenopausal women as a defined subgroup, and the evidence base for flibanserin in perimenopause is extrapolated rather than directly studied. That is an important gap to name honestly. Some clinicians prescribe it off-label in early perimenopause when menstrual cycles are still present, but this represents extrapolation from premenopausal data.

Perimenopause also tends to worsen metabolic health. Liver fat accumulates more rapidly after the hormonal shifts of menopause transition, partly due to declining estrogen. A perimenopausal woman with worsening metabolic syndrome may be developing hepatic steatosis precisely as her desire concerns arise. This overlap deserves careful clinical attention.

Postmenopause

Flibanserin is not approved for postmenopausal women. The phase 3 BOUQUET trial conducted in postmenopausal women did not meet its primary endpoints with sufficient effect size to support a label expansion. Women who are postmenopausal and have HSDD should be evaluated for other evidence-based options including hormone therapy and, where appropriate, off-label consideration of other agents, none of which are flibanserin.

Women with alcohol-related liver disease

This group deserves specific mention because the two contraindications for Addyi, alcohol and hepatic impairment, overlap completely. A woman with alcohol use disorder or alcohol-related liver disease faces both risks simultaneously. Her treating clinician should document this contraindication clearly in the chart and address the alcohol use disorder as a primary concern, because alcohol-related liver disease can range from fatty liver (potentially reversible with cessation) to cirrhosis (permanent). Even if alcohol use is stopped and liver enzymes normalize, hepatic function testing and imaging should confirm recovery before any hepatically-metabolized drug with a narrow therapeutic index is considered.

The standard Addyi titration schedule (for women without hepatic impairment)

For women who have normal hepatic function, confirmed by history and liver function tests, the approved titration is a fixed single-dose start, not a gradual up-titration. There is no week-one lower dose. The prescribing information specifies:

• Dose: 100 mg orally once daily
• Timing: At bedtime only (taking it at any other time of day increases hypotension risk)
• Trial period: Assess response and tolerability at 8 weeks
• Discontinue if: No improvement in satisfying sexual events or desire score by 8 weeks

This matters here because it clarifies that the "titration" question for flibanserin is not about going from 25 mg to 50 mg to 100 mg the way one might approach an SSRI. The drug is approved at exactly one dose. There is no sub-therapeutic starting dose that could theoretically be used in a woman with hepatic impairment to reduce exposure. The pharmacokinetics do not allow for a dose reduction that would reliably bring plasma levels back into the normal range.

The key clinical trials that established this dosing, specifically the VIOLET and SNOWDROP phase 3 trials, tested 100 mg at bedtime versus placebo over 24 weeks. VIOLET enrolled 1,090 premenopausal women and showed a statistically significant increase in satisfying sexual events and a reduction in distress. Women with hepatic impairment were excluded from these trials, which is precisely why no titration data in that population exists.

Drug interactions that compound hepatic risk

Even in women with normal liver function, CYP3A4 inhibitors dramatically raise flibanserin exposure and are either contraindicated or require a titration pause. This is relevant to the hepatic impairment topic because several drugs commonly used in liver disease further inhibit CYP3A4.

• Fluconazole: A moderate CYP3A4 inhibitor often used for candidiasis, commonly treated in women with immunosuppression from liver disease. Co-administration is contraindicated even in women with normal livers.
• Hormonal contraceptives: Oral contraceptive pills containing ethinyl estradiol are mild CYP3A4 inhibitors and were shown in PK studies to raise flibanserin AUC by approximately 40 percent. In a woman with borderline hepatic function, this interaction adds additional exposure.
• Rifampin and CYP3A4 inducers: These lower flibanserin levels, sometimes used in primary biliary cholangitis, but do not make flibanserin appropriate in that setting.

The point is not that drug interactions replace the hepatic impairment contraindication. The point is that women with liver disease are often on polypharmacy that would compound the contraindication further.

Pregnancy, lactation, and contraception

Pregnancy

Flibanserin is contraindicated in pregnancy. There is no assigned FDA pregnancy category under the new labeling system (PLLR, which replaced the A/B/C/D/X categories after 2015), but the prescribing information states that animal reproductive studies showed embryofetal toxicity at doses producing plasma exposures comparable to the human therapeutic dose. No adequate human pregnancy data exist.

If you are using flibanserin and wish to conceive, discontinue the drug before attempting pregnancy. Because flibanserin is used as a daily medication for a chronic condition rather than a short course, your clinician should discuss a stopping plan and address HSDD management during pregnancy through non-pharmacologic means.

Contraception

There is no specific contraception requirement stated in the flibanserin label in the same way that, for example, isotretinoin requires enrollment in iPLEDGE. The drug is not a known human teratogen in the way thalidomide or valproate are. Given animal embryofetal toxicity data and the absence of human safety data, avoiding unintended pregnancy while taking flibanserin is sensible clinical practice. Women using flibanserin who do not want to become pregnant should use reliable contraception, keeping in mind that combined hormonal contraceptives raise flibanserin exposure by roughly 40 percent, which is worth discussing with your prescriber.

Lactation

Human milk transfer data for flibanserin are not available. The prescribing information advises against breastfeeding during flibanserin use. Flibanserin is approved for premenopausal women, a group that includes postpartum and lactating women, so this is a real clinical scenario. HSDD is common postpartum, driven by prolactin elevation, sleep deprivation, and hormonal shifts. A postpartum woman seeking treatment for low desire should be counseled that flibanserin cannot be used while breastfeeding, and that several non-pharmacologic and hormonal options may be better suited to that life stage.

What to use instead: HSDD treatment options for women with hepatic impairment

Because flibanserin is contraindicated, your clinician needs an alternative strategy. The options below do not represent a complete treatment algorithm, and none has been specifically studied in large hepatic impairment cohorts for HSDD. Clinical judgment is required.

Bupropion (off-label)

Bupropion has the most evidence among off-label options for HSDD. It is metabolized by CYP2D6 rather than CYP3A4 or CYP2C19. In moderate to severe hepatic impairment, bupropion clearance is reduced and the extended-release dose must be reduced, but it is not categorically contraindicated at all levels the way flibanserin is. A small randomized trial by Segraves et al. showed bupropion SR at 300 mg/day improved sexual desire scores versus placebo in women with HSDD. This does not constitute formal approval, and hepatic dosing adjustments apply, but it represents a possible path where flibanserin does not.

Hormone therapy for perimenopausal and postmenopausal women

For women in perimenopause or menopause whose low desire accompanies other menopausal symptoms, The Menopause Society (formerly NAMS) recommends hormone therapy as first-line for vasomotor symptoms and notes beneficial effects on sexual function. Estrogen therapy improves vaginal atrophy, which contributes to painful sex and secondary desire loss. Adding testosterone (off-label in the US) has shown benefit for HSDD in postmenopausal women across multiple trials including the APHRODITE study.

Psychosexual therapy

Cognitive behavioral therapy and mindfulness-based sex therapy have level-1 evidence for HSDD and carry no hepatic contraindication. The Lori Brotto mindfulness-based group therapy program, tested in RCTs, showed clinically meaningful improvements in sexual desire and distress. For women who cannot use pharmacologic options due to liver disease, this is the most evidence-supported non-drug path.

Bremelanotide (Vyleesi)

Bremelanotide is the other FDA-approved HSDD drug, a subcutaneous injection used as-needed rather than daily. It is also contraindicated in women with hepatic impairment due to limited data, so it does not solve this specific problem. Mention it here to be complete: it is not an alternative path for women with liver disease.

Having the conversation with your prescriber

Many women are not routinely screened for hepatic dysfunction before sexual health medications are discussed. If you have any of the following, raise them explicitly before flibanserin is prescribed:

• A history of elevated liver enzymes on any prior blood work
• A diagnosis of fatty liver, NAFLD, NASH, hepatitis B or C, primary biliary cholangitis, or cirrhosis
• PCOS with insulin resistance or obesity, given the high NAFLD prevalence in this group
• A history of heavy alcohol use, even if currently in recovery
• Use of hepatotoxic medications (certain antibiotics, antifungals, antiepileptics, or herbal supplements)

A baseline comprehensive metabolic panel (CMP) with AST, ALT, alkaline phosphatase, bilirubin, and albumin gives meaningful starting information. Formal Child-Pugh scoring or a FibroScan may be warranted if there is any clinical concern. This is not an excessive workup; it is the minimum needed to use flibanserin safely.

"Women with PCOS deserve particular attention before any hepatically-cleared drug is initiated," says Elena Vasquez, MD, WomanRx Clinical Reviewer and board-certified OB-GYN. "The overlap between PCOS-related NAFLD and HSDD is under-recognized, and a routine ALT alone does not capture hepatic synthetic function or fibrosis stage. I routinely order a full liver panel and ask specifically about alcohol use before flibanserin comes anywhere near the prescription pad."

Evidence gaps: what we still do not know

Women have been underrepresented in pharmacokinetic research for most of pharmaceutical history. For flibanserin specifically, the hepatic impairment PK study used a small number of subjects, and the Child-Pugh B and C strata were never formally tested because Child-Pugh A data alone crossed the threshold for contraindication. This means:

• We do not know the exact AUC increase in moderate or severe impairment
• We do not have data on women with NAFLD who have not yet reached formal Child-Pugh A criteria but have reduced CYP enzyme activity from hepatic steatosis
• We do not have data in women whose liver disease is related to hormonal contraceptive-induced cholestasis, a real clinical entity in young women
• The trials that established flibanserin's efficacy (VIOLET, SNOWDROP, DAISY) excluded women with hepatic disease, meaning the drug's benefit-risk profile in this population is entirely unknown

Be candid with yourself and your clinician about this uncertainty. "No data" is not the same as "safe." In this case, the pharmacokinetic signal from the mild-impairment data was strong enough that regulators drew a hard line without needing to test more severe categories.